Inhibrx, Inc. (NASDAQ:INBX) Sees Large Increase in Short Interest

Inhibrx, Inc. (NASDAQ:INBX) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 1,200,000 shares, an increase of 10.1% from the November 30th total of 1,090,000 shares. Based on an average daily volume of 77,600 shares, the days-to-cover ratio is currently 15.5 days. Approximately 12.1% of the shares of the company are short sold.

Inhibrx Stock Up 0.9 %

NASDAQ INBX opened at $15.14 on Tuesday. The stock’s 50-day moving average is $15.12 and its 200-day moving average is $14.64. Inhibrx has a one year low of $10.80 and a one year high of $18.95.

Insider Activity at Inhibrx

In related news, Director Jon Faiz Kayyem acquired 69,686 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was purchased at an average cost of $14.23 per share, for a total transaction of $991,631.78. Following the completion of the purchase, the director now directly owns 51,093 shares of the company’s stock, valued at $727,053.39. The trade was a -374.80 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 22.20% of the company’s stock.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.